iconstar paper   HIV Articles  
Back grey arrow rt.gif
 
 
ASM/ICAAC: Enhanced Exposure of Tenofovir-Diphosphate in Peripheral Blood Mononuclear Cells by Tenofovir Alafenamide Compared With Tenofovir Disoproxil Fumarate
 
 
  Reported by Jules Levin
ASM Microbe, June 16-20, 2016, Boston, MA
 
Joseph M. Custodio, Lillian S. Ting, Julia Z. Zack, Sophia R. Majeed, Mingjin Yan, Lijie Zhong, John Ling, Lance Miles, Martin S. Rhee Gilead Sciences, Inc., Foster City, CA

Clin1

Clin2

*Study drugs taken without regard to food; †FTC/TAF dose: 200/10 mg with boosted protease inhibitors (PIs) and 200/25 mg with unboosted 3rd agents; ‡FTC/TAF 200/10 mg: ATV+RTV (n=53), DRV+RTV (n=84), LPV/r (n=18); FTC/TAF 200/25 mg: DTG (n=26), NVP (n=74), RAL (n=66), EFV (n=8), RPV (n=3), MVC (n=1); §FTC/TDF 200/300 mg: ATV+RTV (n=50), DRV+RTV (n=82), LPV/r (n=18); FTC/TAF 200/25 mg: DTG (n=23), NVP (n=66), RAL (n=73), EFV (n=6), RPV (n=6), MVC (n=6). BL, baseline; eGFR, estimated glomerular filtration rate.

Clin3

Clin4

 
 
 
 
  iconpaperstack View Older Articles   Back to Top   www.natap.org